Mylan Inc.today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for Polyethylene Glycol 3350 and Electrolytes for Oral Solution, USP, the generic version of Braintree Laboratories’ [email protected] laxative.
Polyethylene Glycol 3350 and Electrolytes for Oral Solution had U.S. sales of approximately $14 million for the 12 months ending Sept. 30, according to IMS Health
